Biocartis Group NV (BCART.BR)
| Previous close | 0.6250 |
| Open | 0.6200 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 0.5800 - 0.6290 |
| 52-week range | 0.5120 - 2.5200 |
| Volume | |
| Avg. volume | 137,145 |
| Market cap | 56.699M |
| Beta (5Y monthly) | 1.51 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.1120 |
| Earnings date | 19 Apr 2023 - 24 Apr 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 1.80 |
- GlobeNewswire
Press release Biocartis Group NV: Disclosure of transparency notification
PRESS RELEASE - REGULATED INFORMATION 3 March 2023, 17:40 CET Disclosure of transparency notification Mechelen, Belgium, 3 March 2023 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), announces today, in accordance with Article 14, paragraph 1 of the Belgian Act of 2 May 2007 on the disclosure of major shareholdings in issuers of which shares are admitted to trading on a regulated market and laying down miscellaneous prov
- GlobeNewswire
Press release Biocartis Group NV: Biocartis announces the US FDA 510(k) clearance for the Idylla™ MSI Test
PRESS RELEASE 2 March 2023, 7:00 CET BIOCARTIS ANNOUNCES THE US FDA 510(k) CLEARANCE FOR THE IDYLLA™ MSI TEST Mechelen, Belgium, 2 March 2023 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces the U.S. Food and Drug Administration (FDA) 510(k) clearance1 for its fully automated Idylla™ MSI Test. This 510(k) clearance reinforces Biocartis’ commitment to enable clinical molecular diagnostics in the U.S. Now,
- GlobeNewswire
Press release Biocartis Group NV: Disclosure of Outstanding Voting Securities
PRESS RELEASE - REGULATED INFORMATION 28 February 2023, 17:50 CET Disclosure of Outstanding Voting Securities Mechelen, Belgium, 28 February 2023 – Biocartis Group NV (the "Company" or "Biocartis"), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces that in the course of February 2023 4.50% convertible bonds due 2026 in a principal amount of EUR 1,800 were converted into shares of the Company against the issuance of in total 1,613 shares of the Company. On 24
